Application of Endocrine Therapy Drugs for Breast Cancer in 6 Regions of China from 2011 to 2017

LIU Haoran; WANG Mengmeng; SUN Hui; TANG Jing

doi:10.14009/j.issn.1672-2124.2020.11.024

您当前的位置：

首页 >

文章列表页 >

Application of Endocrine Therapy Drugs for Breast Cancer in 6 Regions of China from 2011 to 2017

更新时间：2022-10-08

- Application of Endocrine Therapy Drugs for Breast Cancer in 6 Regions of China from 2011 to 2017
- Vol. 20, Issue 11, Pages: 1378-1382(2020)
- 作者机构：
  
  复旦大学附属妇产科医院药学部
- 作者简介：
- 基金信息：
- DOI：10.14009/j.issn.1672-2124.2020.11.024
  CLC： R95;R737.9
- Published：2020，
扫描看全文
[1]刘浩然,王萌萌,孙慧,汤静.2011—2017年我国6个地区乳腺癌内分泌治疗药物应用分析[J].中国医院用药评价与分析,2020,20(11):1378-1382.

LIU Haoran, WANG Mengmeng, SUN Hui, et al. Application of Endocrine Therapy Drugs for Breast Cancer in 6 Regions of China from 2011 to 2017. [J]. 20(11):1378-1382(2020)
[1]刘浩然,王萌萌,孙慧,汤静.2011—2017年我国6个地区乳腺癌内分泌治疗药物应用分析[J].中国医院用药评价与分析,2020,20(11):1378-1382. DOI： 10.14009/j.issn.1672-2124.2020.11.024.

LIU Haoran, WANG Mengmeng, SUN Hui, et al. Application of Endocrine Therapy Drugs for Breast Cancer in 6 Regions of China from 2011 to 2017. [J]. 20(11):1378-1382(2020) DOI： 10.14009/j.issn.1672-2124.2020.11.024.

摘要

目的:研究我国6个地区（北京、广州、杭州、天津、成都和上海）乳腺癌内分泌治疗药物的应用现状及发展趋势。方法:根据销售金额、用药频度（defined daily dose system

DDDs）、限定日费用（defined daily cost

DDC）及增长情况

对2011—2017年上述6个地区乳腺癌内分泌治疗药物的应用情况进行统计

并分析乳腺癌内分泌治疗用药的使用特点及变化趋势。结果:2011—2017年

上述6个地区参与本次处方分析项目医院的乳腺癌内分泌治疗药物的销售金额由1 191.53万元增至3 406.93万元

增幅为186%;其中

来曲唑、阿那曲唑的销售金额占比排序始终居前2位;来曲唑、他莫昔芬及阿那曲唑的DDDs排序均居前3位;亮丙瑞林的DDC排序均居首位。结论:上述6个地区乳腺癌内分泌治疗药物的处方量及销售金额整体上处于增长趋势;结合相关指南及共识

临床医师在制定药物治疗方案时

能够充分考虑用药的安全性、有效性和经济性

作出综合判断。

Abstract

OBJECTIVE: To study the current situation and development trend of endocrine therapy drugs for breast cancer in 6 regions of China（ Beijing

Guangzhou

Hangzhou

Tianjin

Chengdu and Shanghai）. METHODS:The application of endocrine therapy drugs for breast cancer in the mentioned regions from 2011 to 2017 was statistically analyzed in terms of consumption sum

defined daily dose system（ DDDs）

defined daily cost（ DDC）growth. And the characteristics of drug-use and changes of endocrine therapy drugs for breast cancer were analyzed.RESULTS: From 2011 to 2017

the consumption sum of endocrine therapy drugs for breast cancer in the mentioned regions participating in this prescription analysis project increased from 11 915 300 yuan to 34 069 300 yuan

with an increase of 186%. Among all drugs

letrozole and anastrozole dominated the top two places ranked by cumsumption

while DDDs of letrozole

tamoxifen and anastrozole ranked in the top 3

and DDC of leuprorelin took the lead.CONCLUSIONS: Prescription quantity and consumption sum of endocrine therapy drugs for breast cancer in 6 regions of China are on the rise as a whole. In combination with relevant guidelines and requirements for disease treatment

clinicians should make comprehensive judgment after fully considering the safety

efficacy and economy of drugs when formulate rational treatment plans.

关键词

乳腺癌内分泌治疗药物用药金额用药频度限定日费用

Keywords

Breast cancerEndocrine therapy drugsConsumption sumDefined daily dose systemDefined daily cost

references

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Investigation and Analysis of Application of Tamoxifen and Toremifene in the Treatment of Breast Cancer in 15 Grade Ⅲ,Level A Hospitals in Shanghai from 2015 to 2019

Application of Anti-HIV Drugs in Outpatient Department of Our Hospital from 2016 to 2020

Analysis on the Application of Oral Lipid-Regulating Drugs in Chinese PLA General Hospital During 2016-2018

Application of Antipsychotic Drugs in the Third People’s Hospital of Kunming from 2016 to 2018

Effects of Continuous Intravenous Infusion of Dexmedetomidine Combined with Oxycodone on Inflammatory Response and Immune Function in Patients with Breast Cancer During General Anesthesia

Related Author

ZHAI Qing

YU Bo

DU Qiong

FAN Jiazuan

WANG Mengmeng

ZHU Xiaohong

JIA Jinmei

ZHENG Yonghong

Related Institution

Dept.of Pharmacy, Tongren Hospital,Shanghai Jiao Tong University School of Medicine

Dept.of Oncology,Shanghai Medical College, Fudan University

Dept.of Pharmacy,Fudan University Shanghai Cancer Center

Dept. of Pharmacy, Beijing You’an Hospital, Capital Medical University

Outpatient Pharmacy of Pharmacy Department,Medical Security Center,Chinese PLA General Hospital

⁰